Novartis posts eye drug data amid play for Eylea’s turf


ZURICH (Reuters) – Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
Source :